STTK Stock — Shattuck Labs Inc.: Cash, EV, Pipeline

Share price

$6.01

Market cap

$603.2M

Cash

$208.3M

Enterprise value

$394.9M

Balance sheet

Cash	$208.3M
Debt	$0.0M
Net cash	$208.3M
Enterprise value	$394.9M
Basic shares	100.7M shares
Fully diluted shares	117.8M shares
Fully diluted market cap	$707.7M
Cash per share	$2.07

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading STTK daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	SL-325	Phase 1	Healthy Volunteers	—
Aug 12 - Sep 23	SL-325	Phase 2	Crohn's Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SL-325

Phase 1 · Active Modality: monoclonal antibody

Target DR3 (Death Receptor 3/TNFRSF25)

Indications

Crohn's disease (Phase 1)

Catalysts

— None
— None

Status note Lead program. Completed a single and multiple ascending dose Phase 1 trial in healthy volunteers; data shared June 2026.

SL-846

Preclinical · Active Modality: bispecific antibody

Target DR3 / IL-23R

Indications

Inflammatory bowel disease and other immune-mediated indications (Preclinical)

Catalysts

— None
— None

Status note Bispecific product candidate binding DR3 and IL-23 receptors. GLP toxicology study in cynomolgus macaques currently underway.

SL-425

Preclinical · Active Modality: monoclonal antibody

Target DR3 (Death Receptor 3/TNFRSF25)

Status note Half-life extended version of SL-325; ongoing IND-enabling chronic GLP toxicity study; further development may be informed by SL-325 Phase 1 data.

SL-172154

Stage not disclosed · Terminated

Status note Discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SL-325
Lead indication	Crohn's Disease
Lead phase	Phase 2
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07753850	Phase 2	Not yet recruiting	Sponsor	STTK	—	Crohn's Disease	—
NCT07158437	Phase 1	Active, not recruiting	Sponsor	STTK	—	Healthy Volunteers	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Shattuck Labs, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
OrbiMed Advisors	6,306,127	no change	0.83%	2026-08-14
Frazier Life Sciences	3,750,000	+3,750,000	0.57%	2026-08-14
Sphera Biotech	86,461	-194,325	0.09%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

STTK — Shattuck Labs Inc.